84 results about "Allergic inflammation" patented technology

This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.

Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.

This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.

The invention provides methods and compositions for treating allergic inflammation by combining cytokine antagonists capable of acting synergistically to reduce allergic inflammation in a subject. Methods of in vivo screening for therapeutically effective cytokine antagonists useful for treating allergic inflammation are also provided.

The present invention relates to methods for delivery of fusion polypeptides into cells. Methods are provided for local delivery of fusion polypeptides, e.g., through the skin, eye and the airway, to prevent allergic inflammation, airway hyper-responsiveness and to block T cell activation. Methods for delivery of fusion polypeptides to suppress graft rejection are also provided.

Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.

Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the EG status of the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EG in a subject. Embodiments of the invention are also directed to use of CDH26 as a marker for EG, eosinophilic esophagitis, or allergic inflammatory conditions. Embodiments of the invention also relate to the use of anti-CDH26-based therapeutics to treat allergic inflammatory conditions.

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are tetrahydroquinoline derivatives.

The invention relates to a composition for preventing or treating allergic diseases by using black rice extract and the therapeutic application of the composition. More specifically, the present invention relates to a composition for preventing or treating allergic diseases, which composition contains the following substances as active ingredients: pelargonidin, cyanidin glycoside or containing pelargonidin and Black rice extract of anthocyanins; the invention also relates to the therapeutic use of said composition. Anthocyanin, anthocyanin or black rice extract containing anthocyanin and anthocyanin inhibit the aggregation of eosinophils in the tissue, and thus have an inhibitory effect on allergic inflammation, so the above substances can be effectively For the prevention or treatment of allergic diseases associated with inflammation and eosinophil accumulation, such as allergic rhinitis, allergic conjunctivitis, asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic Sexual diarrhea etc.

Disclosed are methods for treating or preventing allergic inflammation in a subject and methods for treating or preventing one or more symptoms of allergic inflammation in a subject. The methods include administering to the subject a compound which inhibits reactive oxygen species. Also disclosed are methods for reducing a non-animal-derived allergen's ability to initiate an allergenic process and for reducing prooxidant activity of a non-animal-derived allergen. The methods include contacting the non-animal-derived allergen with an agent which inhibits reactive oxygen species. Methods for screening a compound for its usefulness as an agent for reducing a non-animal-derived allergen's ability to initiate an allergenic process and/or for its usefulness as a therapeutic agent for treating or preventing allergic inflammation and/or the symptoms associated therewith are also disclosed.

Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and/or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma. Specifically, the invention provides a method for detection of predisposition to atopic disorders/other immunological disorders such as, autoimmune disorders, inflammatory disorders, cancer, multiple sclerosis, fibrosis, tuberculosis, sarcoidosis, hypertension and disorders developing due to hypertension, diabetes and disorders developing due to diabetes, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease (COPD), cholecystectomy, degenerative joint disease (DJD), seizure disorder, arthritis, etc. where human Inositol polyphosphate 4-phosphatase (INPP4A) might play an important role due to its involvement in platelet action.

The present invention provides for the use of a calpain inhibitor for the treatment of allergy diseases, inflammatory diseases and autoimmune diseases. In particular, it has been found that inhibition of calpain within mast cells decreases the release of chemical mediators into the surrounding environment, resulting in a decreased local inflammatory response. The present invention also provides for a method of decreasing IgE-dependent mast cell degranulation, mast cell mediator release and cytokine production in mast cells, comprising the step of administering to the mast cells an effective amount of a calpain inhibitor.

The invention relates to a desloratadine external preparation and a preparation method thereof. The external preparation takes desloratadine as a main drug and is used for treating allergic skin inflammation. The desloratadine external preparation can increase the concentration of free drug in skin local tissues of the part with the allergic skin inflammation of a body through percutaneous absorption, have an effective histamine sensitization antagonism role, better play local antianaphylaxis and anti-inflammation efficacies and reduce adverse reactions. The external formulation does not pass through the gastrointestinal tract, thereby avoiding the first pass effect and reduce the probability of occurrence of adverse reactions. The external preparation can be directly applied at the affected side, and the onset of action is rapid. Furthermore, the dose and the coverage area of the external preparation can be selected according to the area and the severity of the affected site, and the external preparation is convenient to use and convenient to carry.

The invention discloses application of gentiopicroside and a gentiopicroside preparation, particularly discloses non-treatment application of the gentiopicroside serving as a calcineurin (CAN)-NF-AT pathway blocker and application of the gentiopicroside to preparation of the calcineurin (CAN)-NF-AT pathway blocker, and further discloses application of the gentiopicroside to preparation of an external preparation or daily chemical product for preventing or treating skin hypersensitivity inflammatory reaction. The gentiopicroside stemming from dried roots and rhizomes of Gentiana lutea is capable of blocking a CAN-NF-AT pathway to effectively prevent or treat skin allergy symptoms such as eczema and contact dermatitis caused by excessive immune response and can be prepared into various daily chemical products or external preparations. A gentiopicroside synthetic process used herein is mature, preparation cost is low, popularization and application are benefited, and accordingly the gentiopicroside is promising in application prospect.

The invention relates to a compound amoxicillin breast injectant prescription and a preparation method thereof. The compound amoxicillin breast injectant prescription comprises a suspending aid, an antioxidant and a solid dispersion carrier which are prepared through a special process to obtain white to off-white oily suspension. The compound amoxicillin breast injectant prescription disclosed by the invention has the advantages of simple preparation process, stable content, easy injection and the like. The composition disclosed by the invention is compounded from amoxicillin, clavulanate potassium and prednisolone; compared with other amoxicillin patent preparations, the composition has drug-tolerant bacteria for penicillins, and also has a high inhibition effect on the chromosome exzymes generated by klebsiella peneumoniae, bacillus proteus vulgaris and bacteroides fragilis; prednisolone has anti-inflammatory and antiallergic functions, and has a synergistic effect on bacterial infection and allergic inflammation.